Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06428409 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
A Phase 1 study of Colorectal Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 220
- Enrollment target
- 20
- Study locations
NCT06428409 is a Phase 1 study of Colorectal Cancer and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 220 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT06428409, a Phase 1 study of Colorectal Cancer and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 220 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn: * About the safety of sacituzumab tirumotecan alone or with other treatments and if people tolerate it * How many people have the cancer respond (get smaller or go away) to treatment
Conditions Studied
Interventions
- BIOLOGICAL Sacituzumab tirumotecan
- DRUG Supportive care measures
- DRUG Fluorouracil (5-FU)
- DRUG Leucovorin (LV) or levoleucovorin
- DRUG Rescue medication
Study Locations (20)
Colorado
- University of Colorado Anschutz Medical Campus ( Site 0299) - Aurora
- University of Colorado Anschutz Medical Campus ( Site 0325) - Aurora
- University of Colorado Anschutz Medical Campus ( Site 0326) - Aurora
Florida
- University of Florida College of Medicine ( Site 0281) - Gainesville
- Mount Sinai Cancer Center ( Site 0287) - Miami Beach
New York
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0327) - Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0324) - New York
Victoria
- Epworth Freemasons ( Site 0005) - East Melbourne
- Frankston Hospital-Oncology and Haematology ( Site 0004) - Frankston
California
- UCLA ( Site 0317) - Los Angeles
District of Columbia
- Sibley Memorial Hospital ( Site 0310) - Washington D.C.
Georgia
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0303) - Marietta
Texas
- University of Texas MD Anderson Cancer Center ( Site 0316) - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2024-06-20 |
| Est. Completion | 2029-10-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06428409
The ClinicalTrials.gov registry entry for NCT06428409 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (85% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Sacituzumab tirumotecan is the first listed.
NCT06428409 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Colorado, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06428409 about?
NCT06428409 is a clinical study titled "A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)". Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surge...
What is the current status of trial NCT06428409?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2024-06-20. Estimated completion is 2029-10-16.
What conditions does trial NCT06428409 study?
This clinical trial studies the following conditions: Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer.
What interventions are being tested in trial NCT06428409?
The interventions under investigation include: Sacituzumab tirumotecan (BIOLOGICAL), Supportive care measures (DRUG), Fluorouracil (5-FU) (DRUG), Leucovorin (LV) or levoleucovorin (DRUG), Rescue medication (DRUG).
Who is sponsoring clinical trial NCT06428409?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06428409 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.